吡格列酮联合缬沙坦治疗早期糖尿病肾病疗效观察.docVIP

吡格列酮联合缬沙坦治疗早期糖尿病肾病疗效观察[摘要] 目的 探讨吡格列酮与缬沙坦联合治疗早期糖尿病肾病的临床疗效。 方法 将56例早期糖尿病肾病患者分成治疗组（30例）和对照组（26例），对照组采用缬沙坦单一治疗，治疗组采用吡咯列酮与缬沙坦联合治疗，比较两组24 h尿微量白蛋白（24 h MALB）、空腹血糖（FPG）、收缩压（SBP）、糖化血红蛋白（HbA1c）和C反应蛋白（CRP）的变化。 结果 与治疗前比较，两组治疗后24 h MALB、HbA1c均有下降（均P ＜ 0.05），治疗后治疗组与对照组24 h MALB（t = 2.023）、FPG（t = 2.440）、HbA1c（t = 2.139）疗效比较差异均有统计学意义（均P ＜ 0.05）。 结论 吡格列酮与缬沙坦联合应用是治疗早期糖尿病肾病有效的方法。 [关键词] 早期糖尿病肾病；吡格列酮；缬沙坦；24 h尿微量白蛋白 [中图分类号] R587.2 [文献标识码] A [文章编号] 1673-7210（2012）01（b）-093-02 Observation of curative effects on Pioglitazone combined with Valsartan in the treatment of early diabetic nephropathy SONG Quanchao WANG Sihong XIAO Housheng Department of Endocrinology, Xuancheng People’s Hospital, Anhui Province, Xuancheng 242000, China [Abstract] Objective To investigate the curative effects of Pioglitazone combined with Valsartan in the treatment of early diabetic nephropathy. Methods 56 patients with early diabetic nephropathy were divided into treatment group (30 cases) and control group (26 cases). The control group was given Valsartan only, and the treatment group was given Pioglitazone combined with Valsartan. The 24-hour urine microalbumin (24 h MALB), fasting plasma glucose (FPG), systolic blood pressure (SBP), glycosylated hemoglobin (HbA1c) and C-reactive protein (CRP) changes of the two groups were compared. Results Compared with before treatment, the 24 h MALB and HbA1c after treatment were decreased in both groups (all P ＜ 0.05). After treatment, the curative effects differences in the 24 h MALB (t = 2.023), FPG (t = 2.440) and HbA1c (t = 2.139) between the treatment group and control group were statistically significant (all P ＜ 0.05). Conclusion: Pioglitazone combined with Valsartan is effective in the treatment of early diabetic nephropathy. [Key words] Early diabetic nephropathy; Pioglitazone; Valsartan; 24-hour urine microalbumin 我国糖尿病（diabetes mellitus，DM）发病率逐年升高，糖尿病肾病（diabetic nephropathy，DN）是糖尿病常见的慢性微血管并发症之一，DN引发的终末期肾功能衰竭成为威胁DM患者生命的重要原因。积极的早期干预治疗，可明显延